Holen Sie sich die Stockscreener-App
26.61
1.30%
-0.35
Handel nachbörslich:
26.61
Schlusskurs vom Vortag:
$26.96
Offen:
$26.73
24-Stunden-Volumen:
1.46M
Relative Volume:
1.42
Marktkapitalisierung:
$2.08B
Einnahmen:
$399.58M
Nettoeinkommen (Verlust:
$-54.04M
KGV:
-35.48
EPS:
-0.75
Netto-Cashflow:
$40.13M
1W Leistung:
-2.03%
1M Leistung:
-15.20%
6M Leistung:
-38.04%
1J Leistung:
+26.77%
1-Tages-Spanne:
$26.32
$27.54
1-Wochen-Bereich:
$26.27
$27.97
52-Wochen-Spanne:
$19.73
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Firmenname
Veracyte Inc
Sektor
Branche
Telefon
(650) 243-6300
Adresse
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie VCYT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
26.61 | 2.13B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-16 | Eingeleitet | UBS | Buy |
| 2024-10-10 | Eingeleitet | Guggenheim | Buy |
| 2024-02-23 | Bestätigt | Needham | Buy |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-11-18 | Fortgesetzt | Goldman | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Outperform |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2019-07-31 | Eingeleitet | Lake Street | Buy |
| 2019-07-02 | Eingeleitet | Needham | Buy |
| 2018-11-29 | Herabstufung | Janney | Buy → Neutral |
| 2018-10-31 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-07 | Herabstufung | Janney | Buy → Neutral |
| 2017-11-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Fortgesetzt | BTIG Research | Buy |
| 2016-11-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-18 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-11 | Bestätigt | Leerink Partners | Outperform |
| 2013-11-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO - MSN
Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research - BioSpace
Veracyte (VCYT) Showcases Findings at ASCO Annual Meeting | VCYT Stock News - GuruFocus
Veracyte to present multiple abstracts at ASCO - TipRanks
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research | VCYT Stock News - GuruFocus
Veracyte Inc (VCYT) Shares Gap Down to $26.74 on May 28 - GuruFocus
Veracyte: Upgrading To Neutral (NASDAQ:VCYT) - Seeking Alpha
Captrust Financial Advisors Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Scotiabank maintains Veracyte stock with $44 target - Investing.com
Deutsche Bank AG Has $3.22 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte to Participate in Upcoming Investor Conferences - 01net
Veracyte to Participate in Upcoming Investor Conferences | VCYT Stock News - GuruFocus
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally? - Zacks Investment Research
BNP Paribas Financial Markets Sells 55,684 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
William Blair Estimates Veracyte’s Q2 Earnings (NASDAQ:VCYT) - Defense World
Stifel Financial Corp Sells 2,211 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte projects strong Decipher and Afirma growth, targets 22.5% adjusted EBITDA margin for 2025 - MSN
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next - simplywall.st
Veracyte, Inc. Just Recorded A 260% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Veracyte (VCYT) and Inotiv (NOTV) - The Globe and Mail
Veracyte First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Veracyte Inc earnings beat by $0.29, revenue topped estimates - Investing.com Nigeria
Veracyte (VCYT) Target Price Lowered by UBS | VCYT Stock News - GuruFocus
What Makes Veracyte (VCYT) a New Buy Stock - Yahoo Finance
Veracyte shares target cut to $41 by Needham, keeps buy rating - Investing.com Nigeria
Veracyte, Inc. (NASDAQ:VCYT) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Price Target for Veracyte (VCYT) Amid Growth Potential | VCYT Stock News - GuruFocus
UBS Cuts Price Target on Veracyte to $42 From $49, Keeps Buy Rating - marketscreener.com
VERACYTE, INC. SEC 10-Q Report - TradingView
Breaking Down Veracyte: 7 Analysts Share Their Views - Benzinga
Veracyte (VCYT) Target Price Lowered by Needham Analyst | VCYT Stock News - GuruFocus
Veracyte: Q1 Earnings Snapshot - Norwalk Hour
Veracyte Inc (VCYT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions - Yahoo Finance
Veracyte Inc (VCYT) Q1 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Veracyte Reports Strong Q1 2025 Financial Growth - TipRanks
Veracyte (VCYT) Reports Strong Q1 Growth Driven by Decipher and Afirma - GuruFocus
Veracyte Announces First Quarter 2025 Financial Results - BioSpace
Veracyte Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Veracyte Q1 2025 sees strong revenue growth, stock surges - Investing.com Australia
Veracyte Inc (VCYT) Q1 2025 Earnings: EPS of $0.09 Beats Estimat - GuruFocus
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Veracyte Q1 2025 slides: 18% revenue growth, transition to profitability By Investing.com - Investing.com South Africa
Veracyte Q1 2025 slides: 18% revenue growth, transition to profitability - Investing.com
Finanzdaten der Veracyte Inc-Aktie (VCYT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
1.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):